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Introduction
It is well established that prolonged exercise results in
delayed-onset muscle soreness (DOMS) which peaks after
24 - 48 hours and subsides after 5 - 7 days.8 This has been
attributed to actual tissue damage which occurs during
repetitive contraction of muscle fibres. The damage has
been shown to be further exacerbated when the eccentric
component of contraction is increased, as occurs during
downhill long-distance running when muscles are used in a
braking  motion.17,18,20
The Comrades Marathon, a gruelling 90 km downhill foot
race from Pietermaritzburg to Durban, South Africa, causes an
intense, systemic, exercise-induced inflammatory response.
As the evidence regarding the effect of vitamin C (VC) supple-
mentation on systemic markers of inflammation following
eccentric exercise is presently conflicting showing either no
effect,10,11,14 an attenuation2,19 or evidence of an increased pro-
inflammatory response,5,15 it was the purpose of this study to
reinvestigate and extend on our previous study
15
on the effect
of oral VC supplementation on markers of the acute phase
response and muscle damage following ultramarathon running
in a more extensive work.  We therefore undertook to examine
the effects of supplementation using higher and lower dosages
of VC in the same event 2 years later.
Methods
Study design
Approval to conduct the study was obtained from the Human
Ethics Committee of the Nelson Mandela Medical School of
the University of KwaZulu-Natal. Forty-five registered
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Abstract
Objective. To investigate the effects of vitamin C (VC)
supplementation on the alterations in systemic markers of
inflammation as a result of participation in a 90 km down
run  from Pietermaritzburg to Durban in 29 subjects who
completed the 1999 Comrades Marathon. 
Interventions. Runners were divided into groups receiv-
ing 500 mg/day VC (VC500; N = 10), 1 500 mg/day VC
(VC1500; N = 12) or placebo (P, N = 7) for 7 days before
the race, on the day of the race, and for 2 days following
completion. 
Main outcome measures. Each subject recorded dietary
intake before, during and after the race and provided 35
ml blood samples 15 - 18 hours before the race, immedi-
ately post race, 24 hours post race and 48 hours post
race. These were analysed for full blood count, vitamins
A, C and E, glucose, C-reactive protein (CRP), amyloid A,
interleukin-6 (IL-6) and interleukin-8 (IL-8) concentrations.
All post race concentrations were adjusted for plasma vol-
ume changes. 
Results. Analyses of dietary intakes and blood glucose
and anti-oxidant status on the day preceding the race and
the day of the race excluded carbohydrate intake or plas-
ma vitamins E and A as significant confounders in the
study. Mean pre-race concentrations of serum vitamin C
in VC500 and VC1500 groups (128 – 10.2 and 153 – 10.2
mol/l) were significantly higher (p < 0.01) than in the P
group (83 – 10.8 mol/l) and confirmed the additional
dietary VC intake of both groups. Serum CRP concentra-
tions were significantly higher (p < 0.05) in the VC500
group than in the VC1500 and P groups. This finding was
supported by similar trends in serum amyloid A, plasma
IL-6 and IL-8. When the data from the two VC groups
were pooled and the vitamin intake in the placebo (N = 7)
and VC (N = 22) groups compared, CRP concentrations
in the VC groups were significantly higher at each of the
post-race time points (p < 0.05). 
Conclusion. These data confirm previous findings of a
trend towards an enhanced pro-inflammatory response
following VC intake ≥ 500 mg per day. 
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entrants for the 1999 Comrades Marathon signed informed
consent forms and agreed to participate in the study. They
were divided into 3 groups matched for age, gender, training
status and expected race finishing time: (i) group 1 (placebo
(P)) — placebo supplement (3 placebo tablets per day); (ii)
group 2 (VC500) — one 500 mg VC tablet and 2 placebo
tablets per day; (iii) group 3 (VC1500) — three 500 mg VC
tablets per day.
Each subject was required to take 3 tablets per day over a
10-day period; 1 tablet with breakfast, lunch and supper on the
7 days preceding the race, the day of the race and 2 days fol-
lowing the race. 
The study was double-blinded and based on a 3 (3 groups)
by 4 (4 blood samples) repeated measures design. 
On the day prior to the race, subjects were required to com-
plete 24-hour dietary records of their intake both in terms of
food and supplements, and to report for basic anthropometric
measurements and blood sampling on the afternoon prior to
the race at a time that coincided with their estimated finishing
time (in order to avoid the effect of diurnal rhythms on hormone
concentrations). Within 30 - 45 minutes of completing the race,
the subjects again gave 35 ml blood samples and were asked
to detail their dietary and liquid intakes on the morning of the
race and during the race. The blood sampling was repeated 24
hours and 48 hours after the race and subjects were asked to
record their post-race dietary intakes for a further 36 hours after
the race. 
Dietary analyses
Intake of both food and nutritional supplements were
analysed using the Dietary Manager computer program
(Program Management, Randburg, South Africa). Total daily
carbohydrate (CHO) and VC intakes during the 24 hours
before the race, on the day of the race, and after the race,
including intake derived from any additional CHO supple-
ments used by the athletes, were determined. 
Treatment of blood 
Venous blood samples collected in glass Vacutainer tubes
containing ethylenediaminetetraacetic acid (K3-EDTA) were
used for determination of full blood counts. A 15 ml aliquot
was allowed to clot at room temperature and centrifuged for
10 minutes; aliquots of serum were quick-frozen and stored
at -70…C for later analysis of VC, C-reactive protein (CRP)
and amyloid A. The remainder was drawn into vacutainer
tubes containing K3-EDTA and the plasma stored at -70…C for
later analysis of vitamins E and A, glucose, and interleukin
(IL)-6 and IL-8 concentrations.
Haematological analyses and adjustments
Full blood counts were performed on K3-EDTA- treated spec-
imens using standard haematological procedures on an
automated model (Coulter Electronics Inc., Hialeah, Florida,
USA). Plasma volume changes were determined from pre-
and post-race haemoglobin and haematocrit values using
the method of Dill and Costill6 and all subsequent post-race
concentrations (at 0, 24 and 48 hours) were adjusted for
these plasma volume changes.
Serum acute phase reactants, vitamins C, A and E 
Serum concentrations of the acute phase reactants, CRP
(normal range 0 - 5 g/ml) and amyloid A (normal range 6 -
8 g/ml), were measured using a nephelometric procedure
(Behring Nephelometer II) with reagents purchased from
Behringwerke AG, Marburg, Germany. VC was extracted
from the serum using 20% trichloracetic acid and assayed
using the 2,4-dinitrophenylhydrazine colorimetric method
(Sigma Chemical Co., St Louis, MO, USA), while plasma
concentrations of vitamins A and E were determined using
standard high-performance liquid chromatography (HPLC)
procedures following repeated (x3) extraction with hexane
and using vitamin A-acetate as the internal standard.4
Plasma glucose, IL-6 and IL-8
Plasma glucose concentrations were determined spec-
trophotometrically in pre-race, immediate, 24-hour and 48-
hour post-race samples. The plasma IL-6 and IL-8 analyses
were part of a more comprehensive study on the cytokine
profile of ultramarathon runners,11 but were adjusted for plas-
ma volume changes in this report. These were assayed
using quantitative sandwich enzyme-linked immunosorbent
assay (ELISA) kits provided by R&D Systems, Inc.
(Minneapolis, MN, USA). A standard curve was constructed
using standards provided in the kits. The assays were two-
step sandwich  enzyme immunoassay procedures in which
samples or standards were incubated in 96-well microtiter
plates coated with polyclonal antibodies for the test cytokine
as the capture antibody. Following the appropriate incubation
time, the wells were washed and a second detection anti-
body conjugated to horseradish peroxidase was added. The
plates were incubated and washed, and the amount of
bound enzyme-labelled detection antibody was measured by
adding a chromogenic substrate. The plates were then read
at the appropriate wavelength (450 minus 570 nm). The min-
imum detectable concentration of IL-6 was < 0.094 pg/ml,
and of IL-8 < 10 pg/ml.
Statistical analyses
Data are reported as mean (– standard error of the mean
(SEM)). Due to the small sizes of the groups and the large
variability of the test result values within the groups, conser-
vative non-parametric statistics were used. A Kruskal-Wallis
test was used to compare the mean ranks of the 3 groups at
each of the time points. If this revealed significance, a two-
tailed Wilcoxon s two-sample test was used to establish
whether the difference between the placebo group and the
VC500 or VC1500 groups was significant (p < 0.05). 
The data in the VC500 and VC1500 groups were subse-
quently pooled and an independent, two-sample Mann-
Whitney test was used to establish whether the placebo group
(N = 7) differed significantly from the VC group (N = 22), irre-
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spective of the dosage differences, at each time point. Box and
whisker plots were used to illustrate the variability around the
medians of the 2 groups. A repeated measures analysis of vari-
ance (ANOVA) procedure was used on the logged data to per-
form a profile analysis of each of the measured outcomes.
These data were graphically represented using profile plots
showing the estimated marginal means of the 2 groups as a
function of time. 
Spearman s correlation coefficient was used as a measure
of association. Statistical analysis was executed using SPSS
Inc (Chicago, Illinois) statistical software.
Results
Subject characteristics
Of the initial 45 athletes registered to participate, only 29
completely fulfilled the protocol requirements of the study.
The characteristics of the subjects are given in Table I. There
were no significant differences between the three groups
with regard to age, height, mass, body mass index, training
status, and time taken to complete the ultramarathon.
CHO intake, plasma glucose and vitamins A and E
Mean (– SEM) dietary CHO intakes and plasma concentra-
tions of glucose on the day preceding the race and on the day
of the race are presented in Table II. CHO intake just prior to
and during the race averaged 401 (– 39) g and did not differ
significantly between the groups. Likewise, pre- and post-
race plasma glucose (Table II), vitamin A and vitamin E con-
centrations (not shown) were not different between the 3
groups (p > 0.05).
Blood counts
Selected results of the full blood counts are given in Table III.
Packed cell volume and haemoglobin concentrations indi-
cated a varied hydration status ranging from a mean per cent
plasma volume drop of 1.7% in the VC500 group to 7.1% in
the placebo group in the immediate post-race samples
(Table II). Although 72.5% of the sample (N = 29) presented
with a decrease in plasma volume immediately following
completion of the ultramarathon, the greatest majority
(62.1% and 100%) presented with increases in plasma vol-
ume in the 24-hour and 48-hour post-race samples, respec-
tively. The differences in plasma volume between the groups
did not, however, reach statistical significance (p > 0.05). 
Significant immediate post-race lymphopenia and neu-
trophilia were present in all 3 groups with recovery to normal
values at 24 and 48 hours after completion of the race. The cir-
culating neutrophil count was significantly lower in the VC1500
group (N = 12) in immediate post-race samples, while post-
race lymphopenia was less pronounced in the VC1500 group,
resulting in the immediate post-race neutrophil/lymphocyte
ratio being lowest in this group (p < 0.05). Mean monocyte lev-
els rose significantly in all 3 groups as a result of the prolonged
exertion and remained elevated for the 48-hour post-race peri-
od with no significant differences between the 3 groups.
Serum vitamin C
The results of the serum VC concentrations in the three groups
at the four time-points are shown in Fig. 1. Pre-race serum VC
was significantly higher in the supplemented groups compared
with the P group. The significant mean increase (42.6 µmol/l)
in serum VC in the P group immediately post race was less in
both of the vitamin-supplemented groups (19.3 and -2.84
µmol/l in the VC500 and VC1500 groups, respectively). At 24
and 48 hours after completion of the race the serum VC con-
centrations returned to close to pre-race values.
Circulating concentrations of plasma IL-6 and IL-8
The mean immediate post-race concentrations of the
TABLE I. Subject characteristics (N = 29)
Characteristic Mean (± SEM) Range
Age (yrs) 39.7 (– 1.3) 27 - 54
Body mass (kg) 70.4 (– 2.0) 53.2 - 97.0
Stature (m) 1.74 (– 0.02) 1.57 - 1.89
Body mass index (kg/m2) 23.2 (– 0.5) 18.7 - 28.7
Race time (hrs) 9.73 (– 0.18) 7.38 - 11.08
Weekly training distance (km) 87.9 (– 4.92) 70 - 120
TABLE II. Mean (± SEM) dietary carbohydrate (CHO)
intakes and plasma concentrations of glucose on the
day preceding the race and the day of the race
Plasma 
glucose
CHO (g) (mmol/l)
Day preceding the race
Placebo (N = 7) 399 (– 29.1) 4.69 (– 0.3)
VC500 (N = 10) 499 (– 51.3) 4.95 (– 0.3)
VC1500 (N = 12) 482 (– 42.2) 4.74 (– 0.2)
Day of the race
Placebo (N = 7) 315 (– 54.8) 6.14 (– 0.6)
VC500 (N = 10) 353 (– 35.2) 6.47 (– 0.5)
VC1500 (N = 12) 488 (– 65.7) 5.95 (– 0.3)
Fig. 1. Mean (± SEM) serum vitamin C concentrations
before and after participation in a 90 km ultramarathon (#
p < 0.01, two-tailed Wilcoxon’s test, v. placebo at this time
point).
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chemotactic cytokine, IL-8, were more than 5-fold higher
than mean pre-race concentrations and subsided to close to
pre-race concentrations at 24 and 48 hours after completion
of the race (Table IV). Plasma IL-8 concentrations correlated
strongly (r = 0.67) with absolute neutrophil numbers in the
circulation (Table III). The increase in the mean circulating
concentrations of IL-8, observed immediately post-race,
were greater in the 500 mg group than in the P group, but the
difference did not reach statistical significance (p = 0.14).
Circulating IL-6 concentrations showed a similar trend to
that of IL-8, with a greater than 20-fold increase in concentra-
tions following completion of the downhill ultramarathon, which
subsided within 48 hours. However, throughout the 48-hour
recovery the mean concentrations of IL-6 in the VC500 group
remained elevated above those of the P group, but the differ-
ence did not reach statistical significance (p = 0.11).
Serum CRP and amyloid A concentrations
Both acute phase proteins measured in this study revealed a
similar trend (Figs 2 and 3). When concentrations in the 3
groups were compared at the 24 and 48-hour post-race time-
point a Kruskal-Wallis test revealed a significant difference in
the circulating CRP concentration (p < 0.05). Similar trends
were observed for amyloid-A, but were not statistically sig-
nificant due to large intra-group variance. A subsequent
Wilcoxon s two-sample test revealed significant differences
(p = 0.03; 0.04) between the VC500 and P groups for serum
CRP at the 24 and 48-hour post-race time-points. However,
the increments in mean CRP concentrations were not signif-
Fig. 2. Mean (± SEM) serum CRP concentrations before and
after participation in a 90 km ultramarathon # p < 0.01, two-
tailed Wilcoxon’s test, v. placebo at this time point).
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TABLE III. Haematological profile. Values as mean (± SEM) 
Post-race Post-race Post-race
Variable Pre-race (0.5 - 1 hour) (24 hours) (48 hours) 
% PV change *
Placebo 7.11 (– 2.98) -2.23 (– 3.55) 9.45 (– 2.54)
VC500 1.73 (– 1.80) 7.74 (– 2.26) 12.3 (– 2.25)
VC1500 6,73 (– 2.24) 5.43 (– 2.64) 15.6 (– 2.23)
Total leukocytes(10
9
/l )
Placebo 7.62 (– 1.07) 18.1 (– 2.5) 8.66 (– 1.03) 8.09 (– 1.04)
VC500 7.96 (– 1.09) 16.6 (– 1.2) 9.37 (– 0.68) 7.75 (– 0.31)
VC1500 6.52 (– 0.48) 14.2 (– 1.1) 8.14 (– 0.66) 7.24 (– 0.46)
Neutrophils (10
9
/l)
Placebo 4.43 (– 0.91) 15.2 (– 2.2) 5.14 (– 0.13) 4.04 (– 0.79)
VC500 4.82 (– 1.08) 13.8 (– 0.9) 5.64 (– 0.57) 3.59 (– 0.26)
VC1500 3.45 (– 0.35)+ 11.0 (– 1.0)+ 4.43 (– 0.08) 3.10 (– 1.10)
Lymphocytes (10
9
/l)
Placebo 2.11 (– 0.12) 1.6 (– 0.3) 2.4 (– 0.3) 2.3 (– 0.3)
VC500 2.21 (– 0.12) 1.3 (– 0.1) 2.6 (– 0.2) 2.2 (– 0.1)
VC1500 2.25 (– 0.21) 2.0 (– 0.3)+ 2.7 (– 0.2) 2.4 (– 0.2)
Neutro/lymph ratio
Placebo 2.10 (– 0.37) 11.9 (– 2.3) 2.5 (– 1.5) 2.2 (– 1.1)
VC500 2.31 (– 0.62) 10.7 (– 1.3) 2.4 (– 0.9) 1.7 (– 0.5)
VC1500 1.53 (– 0.25) 7.0 (– 1.9)+ 2.0 (– 1.5) 1.5 (– 0.8)
Monocytes (10
9
/l)
Placebo 0.46 (– 0.05) 1.36 (– 0.15) 0.76 (– 0.10) 0.73 (– 0.10)
VC500 0.61 (– 0.07) 1.00 (– 0.25) 1.00 (– 0.10) 0.76 (– 0.06)
VC1500 0.61 (– 0.05) 1.05 (– 0.14) 0.79 (– 0.07) 0.79 (– 0.05)
*Calculated from packed cell volumes and haemoglobin concentrations; expressed as percentages relative to pre-race plasma volume.
+ P < 0.05 Wilcoxon s test between groups at specified time-point when compared with placebo at this time-point.
PV = plasma volume; neutro/lymph ratio = neutrophil/hymphocyte ratio.
#
#
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icant at any of the post-race time points in the VC1500
group.
However when the data from the 2 VC groups were pooled
(N = 22) and compared with the P group (N = 7), the Mann-
Whitney test showed significant differences of serum CRP con-
centrations between the 2 groups at 0 hours (p = 0.037), 24
hours (p = 0.048) and 48 hours (p = 0.048) post race. In terms
of amyloid A, IL-6 and IL-8, the difference between the 2 groups
was not significant at any of the time-points (p > 0.05). A box
and whisker plot illustrating the variability around the median is
provided in Fig. 4 and indicates that the median of the P group
did lie outside the interquartile range of the VC group at all 3
post-race time-points for serum CRP concentrations. 
Repeated measures ANOVA showed no evidence of an
interaction between the 2 groups over time for serum CRP con-
centrations (p = 0.534). The effect of VC supplementation was
significantly different from the P group at all time-points (f =
6.664, p = 0.016). The profiles of amyloid A and IL-8 were iden-
tical, but co-incident (p = 0.458; 0.861). A profile plot of the
logged serum CRP concentration data is presented in Fig. 5.
Discussion
The results of the serum VC concentrations within the 3
groups confirm significant elevations in the supplemented
groups when compared with those in the P group. In con-
trast, insignificantly different plasma glucose concentrations
in the 3 groups following the race confirm the absence of this
factor as a possible extraneous variable influencing VC
uptake and absorption in the 3 groups.9
Fig. 5. Profile plot of the logged serum CRP concentrations
of the placebo (N = 7) and pooled vitamin C (N = 22) groups
at the four time points.
Fig. 3. Mean (± SEM) serum amyloid A concentrations
before and after participation in a 90 km ultramarathon.
Fig. 4. A box and whisker representation of the variability
of the serum CRP concentrations in placebo (N = 7) and
pooled vitamin C (N = 22) groups at the four time points. 
Pre 0h 24h 48h
Post                   Post Post
Pre 0h post 24h post          48h Post
A
m
yl
o
id
 A
(m
g
/l) 300
250
200
150
100
50
0
A
m
yl
o
id
 A
(m
g
/l)
120
100
80
60
40
20
0
-20
Placebo
VC500
VC1500
Pre 0h 24h 48h
Post                   Post Post
M
ea
n
 l
o
g
 s
er
u
m
 C
R
P
(m
g
/m
l)
2
1.5
1
0.5
0
-0.5
-1
Placebo
Vitamin C
placebo
vitamin C
TABLE IV. Mean (± SEM) plasma interleukin-6 and
interleukin-8 concentrations (adjusted for plasma 
volume changes) 
Post-race Post-race Post-race
Variable Pre-race (0.5 - 1 hour) (24 hours) 48 hours) 
IL-6 (pg/ml)
Placebo 3.6 (– 2.4) 92.5 (– 22.3) 4.7 (– 2.4) 4.2 (– 1.2)
VC500 3.5 (– 1.8) 112 (– 26.3) 6.8 (– 1.8) 4.5 (– 1.8)
VC1500 2.5 (– 0.8) 73.1 (– 6.2) 6.5 (– 1.7) 4.2 (– 1.8)
IL-8 (pg/ml)
Placebo 4.0 (– 0.5) 22.1 (– 4.2) 3.6 (– 0.6) 3.4 (– 0.5)
VC500 3.7 (– 0.7) 28.0 (– 6.6) 3.7 (– 0.7) 3.2 (– 0.7)
VC1500 4.2 (– 1.8) 18.4 (– 2.0) 5.6 (– 0.9) 3.3 (– 0.4)
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When the results of each of the markers of transient sys-
temic inflammatory response syndrome (SIRS) measured in
this study are considered collectively, participation in this 90 km
downhill ultramarathon resulted in evidence of a substantial
pro-inflammatory response which was confirmed by significant
post-race elevations in neutrophil count, plasma IL-6, IL-8,
serum CRP and serum amyloid concentration. This evidence
of SIRS appeared to be exacerbated in the VC500 group when
compared with the placebo and VC1500 groups. 
The development of an inflammatory reaction is known to
be controlled by cytokines. While IL-6 is released from activat-
ed T-helper-2 cells at the site of the damaged tissue, the
chemokine, IL-8, is known to mediate inflammation via its abil-
ity to attract and activate neutrophils in the damaged tissues3
and is a key player in the pro-inflammatory cytokine cascade.
In this study, the mean increase in IL-8 exceeded 500% and
was accompanied by substantial increases in IL-6, as well as
the hepatically derived acute phase proteins, CRP and amyloid
A. Despite the relatively small sample sizes of the 3 groups and
the conservative non-parametric statistics used, serum CRP,
an important marker of acute phase response,7 was signifi-
cantly elevated in the 24-hour post-race sample of the VC500
group when compared with the placebo group. This was sup-
ported by the trends towards higher serum amyloid A 
(p = 0.12), IL-6 (p = 0.11) and IL-8 (p = 0.14) post-race 
concentrations in the VC500 group.
Collectively, these data are also supported by recent find-
ings. The significant increment in the 24-hour post-race acute
phase protein concentration in the VC500 group confirms our
previous finding of an increased acute phase response (CRP)
and reduced anti-inflammatory response (lower serum cortisol
concentrations) reported in the group receiving 1 000 mg VC in
our previous paper.15 The findings of Childs et al.5 who showed
that supplementation with the equivalent of 750 - 1 000 mg VC
daily for 7 days prior to a brief, intense session of eccentric
resistance exercise, resulted in significant increases in indices
of oxidative stress which included serum-free iron, lipid
hydroperoxides and 8-iso prostaglandin F2 alpha, also lend
support to this finding. This contention is further supported by
the significantly lower cortisol and anti-inflammatory cytokine
(Il-10 and IL-1ra) response (reported in Peters et al.14).
Notwithstanding the relatively small sample sizes and the
fact that field work of this nature does not allow strict control of
dietary intakes during the race, the trends of a pro-inflammato-
ry response in the VC500 group are too striking to ignore and
may well support in vitro findings of an ascorbic acid-induced
pro-inflammatory response. These include inhibition of the
hydrogen peroxide (H2O2), neutralising activity of catalase by
complexing with the haeme group of this anti-oxidative
enzyme,12,13 the inability of the vitamin to scavenge H2O21 and its
paradoxical action in preventing the auto-oxidative inactivation
of NADPH-oxidase by acting as a scavenger of hypochlorus
acid (HOCl), which results in increased production of H2O2 by
activated phagocytes.1
Although a pro-inflammatory response could reasonably be
expected to augment innate host defences against microbial
and viral pathogens, possibly contributing to the lower inci-
dence of post-race upper respiratory tract infection in vitamin
C-supplemented ultramarathon athletes,16 this may, however,
be offset by an increase in the potential threat of inflammation-
mediated tissue damage.
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